BrainsWay announced positive results in a recently published post-marketing study of its Deep Transcranial Magnetic Stimulation for the treatment of late-life depression. The data were highlighted in an article entitled, “Never Too Late: Safety and Efficacy of Deep TMS for Late-Life Depression,” that was published in the Journal of Clinical Medicine, an international, peer-reviewed, open access journal. The post-marketing study demonstrated real-world outcomes for older adults suffering from major depressive disorder. In the study, data was analyzed from 247 depression patients at 16 clinical sites in this age group who had been treated with BrainsWay’s proprietary H1 Coil. The results showed a 79.4% response rate and a 60.3% remission rate for those patients who had received at least 30 treatment sessions, and were based on the rating scale that was most utilized for each individual patient. The outcomes were comparable to those reported in a post-marketing analysis of over 1,350 patients published in 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BWAY:
- BrainsWay Enhances Support for Military Mental Health
- Brainsway broadens partnership with Katie’s Way Plus
- BrainsWay Broadens Partnership with Katie’s Way Plus Through Order of an Additional 18 Deep TMS™ Systems
- Brainsway price target raised to $13 from $12 at H.C. Wainwright
- BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights